 SEATTLE, June 09, 2021 GLOBE NEWSWIRE -- Chinook Therapeutics, Inc. Nasdaq: KDNY, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Tom Frohlich, chief business officer, has been promoted to chief operating officer COO of Chinook and Andrew King, D.V.M, Ph.D., head of renal discovery and translational medicine, has been promoted to chief scientific officer CSO of Chinook. 